Morgan Stanley Remains Concerned About C.R. Bard

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Underweight rating and $127.00 price target on C.R. Bard BCR. In the report, Morgan Stanley noted, “The panel unanimously voted Bard's DCB approvable, a key positive for the company's main pipeline product, which we now expect to be approved in late 4Q14/1Q15. Our concerns remain on commercial impact, given panel commentary and comparisons with Medtronic and stent data. We remain Underweight.” C.R. Bard closed on Thursday at $140.98.